

**UNITED STATES SECURITIES AND EXCHANGE
COMMISSION**

Washington, D.C. 20549

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF
SECURITIES**

OMB APPROVAL

OMB Number: 3235-0104

Estimated average burden

hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * <u>Cuneo Andrew</u> (Last) (First) (Middle) <u>1000 MYLAN BOULEVARD</u> (Street) <u>CANONSBURG PA 15317</u> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>03/01/2021</u>	3. Issuer Name and Ticker or Trading Symbol <u>Viatrix Inc [VTRS]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>See Remarks</u>	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
<u>Common Stock</u>	<u>10,123</u>	<u>D</u>	

**Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
<u>Employee Stock Option - Right to Buy</u>	<u>(1)</u>	<u>03/02/2021</u>	<u>Common Stock</u>	<u>4,735</u>	<u>22.66</u>	<u>D</u>	
<u>Employee Stock Option - Right to Buy</u>	<u>(2)</u>	<u>02/22/2022</u>	<u>Common Stock</u>	<u>12,762</u>	<u>23.44</u>	<u>D</u>	
<u>Employee Stock Option - Right to Buy</u>	<u>(3)</u>	<u>03/06/2023</u>	<u>Common Stock</u>	<u>6,005</u>	<u>30.9</u>	<u>D</u>	
<u>Employee Stock Option - Right to Buy</u>	<u>(3)</u>	<u>03/06/2023</u>	<u>Common Stock</u>	<u>4,438</u>	<u>30.9</u>	<u>D</u>	
<u>Employee Stock Option - Right to Buy</u>	<u>(4)</u>	<u>03/05/2024</u>	<u>Common Stock</u>	<u>2,394</u>	<u>55.84</u>	<u>D</u>	
<u>Employee Stock Option - Right to Buy</u>	<u>(5)</u>	<u>03/04/2025</u>	<u>Common Stock</u>	<u>2,364</u>	<u>55.61</u>	<u>D</u>	
<u>Employee Stock Option - Right to Buy</u>	<u>(6)</u>	<u>02/17/2026</u>	<u>Common Stock</u>	<u>3,679</u>	<u>46.27</u>	<u>D</u>	
<u>Employee Stock Option - Right to Buy</u>	<u>(7)</u>	<u>03/03/2027</u>	<u>Common Stock</u>	<u>4,421</u>	<u>45.18</u>	<u>D</u>	
<u>Employee Stock Option - Right to Buy</u>	<u>(8)</u>	<u>03/02/2028</u>	<u>Common Stock</u>	<u>5,906</u>	<u>40.97</u>	<u>D</u>	
<u>Restricted Stock Units</u>	<u>(9)</u>	<u>(9)</u>	<u>Common Stock</u>	<u>1,208</u>	<u>0.00</u>	<u>D</u>	
<u>Restricted Stock Units</u>	<u>(10)</u>	<u>(10)</u>	<u>Common Stock</u>	<u>6,040</u>	<u>0.00</u>	<u>D</u>	
<u>Employee Stock Option - Right to Buy</u>	<u>(11)</u>	<u>03/01/2029</u>	<u>Common Stock</u>	<u>4,693</u>	<u>27.45</u>	<u>D</u>	

**Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Restricted Stock Units	(12)	(12)	Common Stock	5,239	0.00	D	
Restricted Stock Units	(13)	(13)	Common Stock	9,822	0.00	D	
Employee Stock Option - Right to Buy	(14)	03/02/2030	Common Stock	7,381	17.48	D	
Restricted Stock Units	(15)	(15)	Common Stock	13,730	0.00	D	
Restricted Stock Units	(16)	(16)	Common Stock	17,163	0.00	D	

Explanation of Responses:

1. These options vested on March 2, 2014.
2. These options vested on February 22, 2015.
3. These options vested on March 6, 2016.
4. These options vested on March 5, 2017.
5. These options vested on March 4, 2018.
6. These options vested on February 17, 2019.
7. These options vested on March 3, 2020.
8. 1,969 of these options vested on March 2, 2019, 1,968 vested on March 2, 2020 and 1,969 will vest on March 2, 2021.
9. Each restricted stock unit (RSU) represents the right to receive one share of common stock of Viatrix Inc. ("Viatrix"). These RSUs will vest on March 2, 2021.
10. Each RSU represents the right to receive one share of common stock of Viatrix Inc. These RSUs will vest in full on March 2, 2021.
11. 1,564 of these options vested on March 2, 2020, 1,564 will vest on March 2, 2021 and 1,565 will vest on March 2, 2022.
12. Each RSU represents the right to receive one share of common stock of Viatrix. 2,619 of the RSUs will vest on March 2, 2021 and 2,620 will vest on March 2, 2022.
13. Each RSU represents the right to receive one share of common stock of Viatrix. These RSUs will vest in full on March 2, 2022.
14. 2,461 of these options will vest on March 2, 2021 and 2,460 will vest on each of March 2, 2022 and March 2, 2023.
15. Each RSU represents the right to receive one share of common stock of Viatrix. 4,577 of these RSUs will vest on March 2, 2021, 4,576 will vest on March 2, 2022 and 4,577 will vest on March 2, 2023.
16. Each RSU represents the right to receive one share of common stock of Viatrix. These RSUs will vest in full on March 2, 2023.

Remarks:

President, JANZ (Japan, Australia and New Zealand) Exhibit 24 - Power of Attorney

/s/ Kevin Macikowski, by 03/04/2021
power of attorney.

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

The undersigned hereby appoints each of Brian S. Roman, Thomas D. Salus and Kevin D. Macikowski, or any of them signing singly, and with full power of substitution, the undersigned's true and lawful attorney-in-fact to:

- (1) prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the U.S. Securities and Exchange Commission (the "SEC") a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or any rule or regulation of the SEC;
- (2) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of Viatris Inc. (the "Company"), Forms 3, 4, and 5 in accordance with Section 16(a) of the Exchange Act and the rules thereunder and any other forms or reports the undersigned may be required to file in connection with the undersigned's ownership, acquisition, or disposition of securities of the Company;
- (3) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5 or any amendment or amendments thereto, and timely file such form with the SEC and any stock exchange or similar authority; and
- (4) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act and the rules thereunder.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 1st day of March, 2021.

/s/ Andrew Cuneo

Signature

Andrew Cuneo

Print Name